The Optic Neuropathy drugs in development market research report provides comprehensive information on the therapeutics under development for Optic Neuropathy, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Optic Neuropathy. Buy the report here.
Smarter leaders trust GlobalData
The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Optic Neuropathy and features dormant and discontinued products.
GlobalData tracks 16 drugs in development for Optic Neuropathy by 15 companies/universities/institutes. The top development phase for Optic Neuropathy is preclinical with 13 drugs in that stage. The Optic Neuropathy pipeline has 12 drugs in development by companies and four by universities/ institutes. Some of the companies in the Optic Neuropathy pipeline products market are: Abeona Therapeutics, Astellas Pharma and TNF Pharmaceuticals.
The key targets in the Optic Neuropathy pipeline products market include Prolow Density Lipoprotein Receptor Related Protein 1, Neuropilin 1, and Microtubule Associated Serine/Threonine-Protein Kinase 2.
The key mechanisms of action in the Optic Neuropathy pipeline product include Erythropoietin Receptor Agonist with one drug in Phase II. The Optic Neuropathy pipeline products include eight routes of administration with the top ROA being Intravitreal and eight key molecule types in the Optic Neuropathy pipeline products market including Synthetic Peptide, and Gene Therapy.
Optic Neuropathy overview
Optic neuropathy is an inherited form of vision loss. Symptoms include eye pain or discomfort, numbness, tingling, and clouding of vision. Predisposing factors include age, smoking, alcohol, cancer treating drugs, stress related chemicals, some antibiotics, and cyanogens.
For a complete picture of Optic Neuropathy’s pipeline drug market, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.
